Edition:
United Kingdom

Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

124.11USD
18 Oct 2018
Change (% chg)

$-2.17 (-1.72%)
Prev Close
$126.28
Open
$125.89
Day's High
$125.89
Day's Low
$122.67
Volume
57,827
Avg. Vol
107,511
52-wk High
$220.09
52-wk Low
$77.60

Select another date:

Thu, Aug 2 2018

Photo

Chinese biotech BeiGene raises $903 million in HK's first secondary listing under new rules: sources

HONG KONG (Reuters/IFR) - Chinese Nasdaq-listed biotech BeiGene Ltd has raised $903 million after pricing its secondary listing in Hong Kong - the first under new exchange rules - near the top of an indicative range, three people close to the deal said on Thursday.

Chinese biotech BeiGene raises $903 million in Hong Kong's first secondary listing under new rules - sources

HONG KONG (Reuters/IFR) - Chinese Nasdaq-listed biotech BeiGene Ltd has raised $903 million after pricing its secondary listing in Hong Kong - the first under new exchange rules - near the top of an indicative range, three people close to the deal said on Thursday.

UPDATE 1-Chinese biotech BeiGene raises $903 mln in HK's first secondary listing under new rules -sources

* Deal is second under new rules for early-stage biotechs (Adds deal details, context)

Chinese biotech BeiGene raises $903 mln in HK's first secondary listing under new rules -sources

HONG KONG, Aug 2 (Reuters/IFR) - Chinese Nasdaq-listed biotech BeiGene Ltd has raised $903 million after pricing its secondary listing in Hong Kong - the first under new exchange rules - near the top of an indicative range, three people close to the deal said on Thursday.

BRIEF-Beigene Reports Q1 Net Loss per ADS $2.03

* REVENUES FOR THREE MONTHS ENDED MARCH 31, 2018 WERE $32.54 MILLION, COMPARED TO NIL IN SAME PERIOD IN 2017

BRIEF-BeiGene Says CEO John V. Oyler's 2017 Total Compensation Was $10.3 Million

* BEIGENE LTD SAYS CEO JOHN V. OYLER'S 2017 TOTAL COMPENSATION WAS $10.3 MILLION – SEC FILING Source : https://bit.ly/2r6wtIy Further company coverage: (Reuters.Briefs@thomsonreuters.com)

Select another date: